Swiss firm Polyphor has promoted Gökhan Batur from chief commercial officer to chief executive officer. Current chief Giacomo DiNepi is retiring. 24 January 2020
Germany’s Evotec and Indivumed have agreed a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer (NSCLC). 23 January 2020
Shares of US specialty pharma company Baudax Bio were up more than 7% at $7.55 pre-market today, after it announced that the US Food and Drug Administration has set a Prescription Drug User Fee Act (PDUFA) goal date of February 20, 2020 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain. 22 January 2020
Dutch specialty pharma company Pharming has been granted European approval for a new production facility for lead product Ruconest (conestat alfa). 21 January 2020
The European Commission has approved USA-based Rigel Pharmaceuticals’ Tavlesse (fostamatinib) for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. 20 January 2020
Drugmaker Astellas is to build a new manufacturing facility for the active pharmaceutical ingredient (API) of Prograf (tacrolimus hydrate) at the group’s Toyama Technology Center in Japan. 17 January 2020
Israel-based biotech firms Wize Pharma and Bonus BioGroup today announced a collaboration, whereby Bonus will issue $16.4 million worth of its ordinary shares to Wize, in exchange for both 37% of Wize's future LO2A-based revenue (if any) and a $7.4 million investment by Wize into Bonus BioGroup. 16 January 2020
The US Food and Drug Administration has accepted the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations, submitted by Bristol-Myers Squibb. 15 January 2020
Iovance Biotherapeutics has licensed TALEN technology from Cellectis as part of a research and global licensing deal to develop gene-edited tumor infiltrating lymphocytes (TIL). 14 January 2020
Last week we reported that Russian pharmaceutical company Nanolek was cooperating with Israel’s Teva Pharmaceutical Industries on the production of an active ingredient in Russia. 14 January 2020
Bausch Health subsidiary Bausch + Lomb has won approval in Mexico for Vyzulta (latanoprostene bunod), for the reduction of intraocular pressure (IOP) in people with open-angle glaucoma or ocular hypertension. 13 January 2020
Ireland-incorporated Endo International said on Friday that its subsidiaries Endo Pharmaceuticals and Par Pharmaceutical have executed a settlement agreement with the US State of Oklahoma. 11 January 2020
German pharma and crop sciences major Bayer has linked up with US dermatology focussed biotech Azitra in the identification and characterization of skin microbiome bacteria. 10 January 2020
Japan’s Meiji Seika Pharma has entered into an exclusive distribution, license and collaboration agreement for the epigenetic immunomodulator, HBI-8000, with California’s HUYA Bioscience. 10 January 2020
Japan’s Chugai Pharmaceutical’s edged up 2.4% to 10,380 yen by close of trading today, after it said it has entered into a global licensing agreement with Verastem Oncology regarding CKI27 (CH5126766), an investigational anticancer agent under development by Chugai for solid tumors. 9 January 2020
Dutch liver specialist NorthSea Therapeutics has raised $40 million in a series B financing round, funding development of a treatment for non-alcoholic steatohepatitis (NASH). 8 January 2020
Tokyo-based Meiji Seika and New York’s Kadmon Corporation have formed a Japan-domiciled joint venture to exclusively develop and commercialize KD025. 8 January 2020
Incyte has applied for European marketing authorization for pemigatinib, for the treatment of certain adults with locally advanced or metastatic cholangiocarcinoma. 7 January 2020
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024